Tyligand Bioscience patents SHP-2 inhibitors for cancer
Jan. 30, 2025
Tyligand Bioscience Ltd. has prepared and tested tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.